Cytokinetics

Cytokinetics, Incorporated

Headquarters in South San Francisco
Company type	Public
Traded as	Nasdaq: CYTK S&P 400 component
Industry	Biotechnology industry
Founded	1997; 27 years ago (1997)
Founders	James Spudich Ronald Vale James Sabry Lawrence S.B. Goldstein
Headquarters	South San Francisco, California , U.S.
Key people	Robert Blum (president & CEO) Fady Malik (EVP) Ching Jaw (CFO) Stuart Kupfer (CMO)
Products	Omecamtiv mecarbil Reldesemtiv CK-3773274
Revenue	US$7.53 million (2023)
Operating income	US$(496.2 million) (2023)
Net income	US$(526.2 million) (2023)
Total assets	US$824.3 million (2023)
Number of employees	423 (December 2023)
Website	cytokinetics.com
Footnotes / references Financials as of December 31, 2023[update].[1]

Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.